Citation
- Authors: Shih, H. J., Chen, H. H., Chen, Y. A., Wu, M. H., Liou, G. G., Chang, W. W., Chen, L., Wang, L. H., Hsu, H. L.
- Year: 2012
- Journal: Oncotarget
- Applications: in vitro / shRNA plasmid / jetPEI
- Cell types:
- Name: A549
Description: Human lung carcinoma cells, type II pneumocytes
Known as: A-549 - Name: HT1299
- Name: MCF 10A
Description: Human breast adenocarcinoma cells
Known as: MCF10A, MCF 10A
- Name: A549
Abstract
Overexpression of Shc adaptor proteins is associated with mitogenesis, carcinogenesis and metastasis. Multiple copies in T-cell malignancy 1 (MCT-1) oncoprotein promotes cell proliferation, survival and tumorigenic effects. Our current data show that MCT-1 is a novel regulator of Shc-Ras-MEK-ERK signaling and MCT-1 is significantly co-activated with Shc gene in human carcinomas. The knockdown of MCT-1 enhances apoptotic cell death accompanied with the activation of caspases and cleavage of caspase substrates under environmental stress. The cancer cell proliferation, chemo-resistance and tumorigenic capacity are proved to be effectively suppressed by targeting MCT-1. Accordingly, an important linkage between MCT-1 oncogenicity and Shc pathway in tumor development has now been established. Promoting MCT-1 expression by gene hyperactivation may be recognized as a tumor marker and MCT-1 may serve as a molecular target of cancer therapy.